45

Revenue 2017

Zytiga

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Zytiga was produced by Janssen.

Trailing Clovis, AstraZeneca gets FDA approval for Lynparza in prostate cancer

Lynparza is now a second-line treatment option for men with this type of cancer who have progressed after prior treatment with Pfizer’s Xtandi (enzalutamide) or Johnson &Johnson’s Zytiga ... Zytiga or Xtandi in men with BRCA 1/2 and ATM gene mutations

Bayer gets EU nod for prostate cancer drug Nubeqa

Nubeqa’s rivals in the prostate cancer market include J&J’s Erleada (apalutamide) – its follow-up to its Zytiga (abirterone) brand which is now threatened by generic competition – and

J&J gets EMA nod for wider use of Erleada in prostate cancer

Androgen inhibitor Erleada (apalutamide) is J&J’s follow-up up to big-selling prostate cancer drug Zytiga (abiraterone acetate), which has been hit by the loss of patent protection and ... Xtandi is now the dominant player in the market by value, with

Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer

Johnson &Johnson’s Zytiga (abiraterone) or Pfizer’s Xtandi (enzalutamide).

Litigation concerns threaten to overshadow solid quarter at J&J

therapy Zytiga (abiraterone acetate).

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Data provided by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology